Severity of Ischemic Stroke After Left Atrial Appendage Closure vs Nonwarfarin Oral Anticoagulants
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
37999669
DOI
10.1016/j.jacep.2023.10.012
PII: S2405-500X(23)00803-4
Knihovny.cz E-resources
- Keywords
- Rankin scale, anticoagulation, atrial fibrillation, left atrial appendage closure, non-vitamin K oral antagonist, stroke,
- MeSH
- Anticoagulants adverse effects MeSH
- Stroke * epidemiology etiology prevention & control MeSH
- Atrial Fibrillation * complications drug therapy surgery MeSH
- Hemorrhagic Stroke * chemically induced complications drug therapy MeSH
- Ischemic Stroke * chemically induced complications drug therapy MeSH
- Hemorrhage chemically induced MeSH
- Middle Aged MeSH
- Humans MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Left Atrial Appendage Closure MeSH
- Treatment Outcome MeSH
- Warfarin adverse effects MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Anticoagulants MeSH
- Warfarin MeSH
BACKGROUND: Strokes after left atrial appendage closure (LAAC) prophylaxis are generally less severe than those after warfarin prophylaxis-thought to be secondary to more hemorrhagic strokes with warfarin. Hemorrhagic strokes are similarly infrequent with direct oral anticoagulant (DOAC) prophylaxis, so the primary subtype after either LAAC or DOAC prophylaxis is ischemic stroke (IS). OBJECTIVES: The purpose of this study was to compare the severity of IS using the modified Rankin Scale in atrial fibrillation patients receiving prophylaxis with DOACs vs LAAC. METHODS: A retrospective analysis was performed of consecutive patients undergoing LAAC at 8 centers who developed an IS (ISLAAC) compared with contemporaneous consecutive patients who developed IS during treatment with DOACs (ISDOAC). The primary outcome was disabling/fatal stroke (modified Rankin Scale 3-5) at discharge and 3 months later. RESULTS: Compared with ISDOAC patients (n = 322), ISLAAC patients (n = 125) were older (age 77.2 ± 13.4 years vs 73.1 ± 11.9 years; P = 0.002), with higher HAS-BLED scores (3.0 vs 2.0; P = 0.004) and more frequent prior bleeding events (54.4% vs 23.6%; P < 0.001), but similar CHA2DS2-VASc scores (5.0 vs 5.0; P = 0.28). Strokes were less frequently disabling/fatal with ISLAAC than ISDOAC at both hospital discharge (38.3% vs 70.3%; P < 0.001) and 3 months later (33.3% vs 56.2%; P < 0.001). Differences in stroke severity persisted after propensity score matching. By multivariate regression analysis, ISLAAC was independently associated with fewer disabling/fatal strokes at discharge (OR: 0.22; 95% CI: 0.13-0.39; P < 0.001) and 3 months (OR: 0.25; 95% CI: 0.12-0.50; P < 0.001), and fewer deaths at 3 months (OR: 0.28; 95% CI: 0.12-0.64; P < 0.001). CONCLUSIONS: Ischemic strokes in patients with atrial fibrillation are less often disabling or fatal with LAAC than DOAC prophylaxis.
Homolka Hospital Prague Czech Republic
Houston Methodist Houston Texas USA
Icahn School of Medicine at Mount Sinai New York New York USA
Massachusetts General Hospital Boston Massachusetts USA
Pacific Heart Institute Santa Monica California USA
Scripps Health San Diego California USA
St Bernard's Heart and Vascular Center Jonesboro Arkansas USA
References provided by Crossref.org